Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CNTB vs UNCY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UNCY Captures Overall Composite Edge (43.7 HOLD vs 41.0 SELL), While CNTB Leads 4–1 on Growth & Valuation Pillars

UNCY Overall Winner 6-Pillar Tally: CNTB 4 – 1 UNCY (1 Tie) Matrix Metrics: CNTB 3 – 6 UNCY

As of Nov 17, 2026, Unicycive Therapeutics, Inc. (UNCY) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (43.7/100 HOLD vs. 41.0/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. CNTB trades at $0.61 (0.8x Forward P/E, -2384.5% operating margin) versus UNCY at $3.73 (2.5x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: UNCY earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. CNTB 41.0/100 SELL) and 1.02β · 66% Vol risk profile, whereas CNTB leads top-line expansion (+5666.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile UNCY is in a Breakdown options structure phase (RSI 47.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CNTB vs UNCY
CNTB NASDAQ
Connect Biopharma Holdings Limited Ordinary Shares
Pharmaceutical Preparations
$0.61
-5.07% 1D
Market Cap $42.6M
TTM Revenue $3.0M
Forward P/E 0.8x
Beta / 30D Vol 0.92β · 68% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 48.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.7%), weak momentum, RSI 26
RSI-14: 25.6 · SMA20: $0.75 · SMA50: $0.99
UNCY NASDAQ Head-to-Head Winner
Unicycive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.73
+0.68% 1D
Market Cap $97.2M
TTM Revenue N/A
Forward P/E 2.5x
Beta / 30D Vol 1.02β · 66% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 30.0 Fund 50.0 Flow 70.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.6 · SMA20: $3.69 · SMA50: $4.14

6-Pillar Scorecard Institutional Category Breakdown (CNTB 4 – 1 UNCY)

Columns: Metric · CNTB · UNCY
1. Valuation Multiples CNTB
Forward P/E 0.8x 2.5x
Trailing P/E 0.8x 2.0x
PEG Ratio N/M N/M
EV / Revenue 5.5x N/M
2. Growth & Scale CNTB
Revenue Growth (YoY) +5666.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.0M N/A
Market Cap $42.6M $97.2M
3. Profitability & Quality UNCY
Gross Margin 100.0% N/A
Operating Margin -2384.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -140.5% -101.1%
4. Balance Sheet & Cash Flow CNTB
Cash Generation (TTM) -$61M -$28M
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $43M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CNTB
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 397.3% (100th %ile) 79.1% (30th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CNTB (3) vs UNCY (6)
Institutional Metric CNTB UNCY Criterion Row Edge
Market Capitalization
Scale
$42.6M $97.2M Larger Scale UNCY
Trailing P/E Ratio
Valuation
0.8x 2.0x Lower Multiple CNTB
Forward P/E Ratio
Valuation
0.8x 2.5x Lower Multiple CNTB
Revenue Growth (YoY)
Growth
+5666.7% +0.0% Higher Growth CNTB
Operating Margin (TTM)
Profitability
-2384.5% 0.0% Higher Margin UNCY
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-140.5% -101.1% Higher ROE UNCY
52-Week Range Position
Momentum
2% ($1–$4) 7% ($3–$9) Stronger Trend UNCY
Beta / 30D Volatility
Risk Regime
0.92β · 68% Vol 1.02β · 66% Vol Lower Realized Risk UNCY
Unified Institutional Score
Composite Signal
41.0 / 100 (SELL) 43.7 / 100 (HOLD) Higher Composite UNCY
Trailing 12M Revenue (USD)
Operating Scale
$3.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$61M ($26M Net Cash) -$28M ($43M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UNCY +38.29 pp
CNTB: -32.16% · UNCY: +6.13%
3M Horizon UNCY +41.95 pp
CNTB: -75.19% · UNCY: -33.24%
6M Horizon UNCY +20.32 pp
CNTB: -72.13% · UNCY: -51.81%
1Y Horizon UNCY +36.91 pp
CNTB: -71.21% · UNCY: -34.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CNTB Revenue UNCY Revenue CNTB Op. Margin UNCY Op. Margin Margin Leader
FY2022 N/A $0M N/A -1898.2% UNCY
FY2023 N/A $0M N/A -3077.6% UNCY
FY2024 $30M N/A -86.2% N/A CNTB
FY2025 $0M N/A -90740.6% N/A CNTB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CNTB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 397.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CNTB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UNCY BREAKDOWN
129d in phase · OBV NEUTRAL
Current IV 79.1%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact UNCY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CNTB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $42.6M market capitalization and -2384.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
UNCY Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $97.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CNTB vs UNCY Key Questions & Quantitative Answers

As of Nov 17, 2026, Unicycive Therapeutics, Inc. (UNCY) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (43.7/100 HOLD vs. 41.0/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. CNTB trades at $0.61 (0.8x Forward P/E, -2384.5% operating margin) versus UNCY at $3.73 (2.5x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: UNCY earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. CNTB 41.0/100 SELL) and 1.02β · 66% Vol risk profile, whereas CNTB leads top-line expansion (+5666.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile UNCY is in a Breakdown options structure phase (RSI 47.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CNTB leads the Growth & Scale pillar: CNTB posts +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin), compared with UNCY at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), CNTB cumulative revenue shifted N/A while UNCY shifted N/A. In operating R&D and SG&A reinvestment, CNTB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UNCY.

CNTB screens cheaper on headline valuation multiples. CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin), whereas UNCY trades at 2.5x Forward P/E, 2.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNTB (-140.5% ROE) versus UNCY (-101.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk). By comparison, UNCY carries 79.1% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.02β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.